A Phase 3, Randomized, Double-blinded, Placebo-controlled Study of Ularitide in the Treatment of Subjects with Acute Decompensated Heart Failure

Trial Profile

A Phase 3, Randomized, Double-blinded, Placebo-controlled Study of Ularitide in the Treatment of Subjects with Acute Decompensated Heart Failure

Discontinued
Phase of Trial: Phase III

Latest Information Update: 16 Aug 2017

At a glance

  • Drugs Ularitide (Primary)
  • Indications Decompensated heart failure
  • Focus Registrational; Therapeutic Use
  • Sponsors PDL BioPharma
  • Most Recent Events

    • 16 Aug 2017 Status changed from recruiting to discontinued.
    • 28 Jul 2017 This trial has been suspended in Austria.
    • 24 Jun 2011 This trial is recruiting in Lithuania, but has prematurely ended in Finland.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top